What is Celmatix?
Celmatix Inc. operates at the intersection of advanced biotechnology and women's health, focusing on the development of precision therapeutics. The company's core mission is to address significant unmet medical needs through a deep understanding of female physiology. Their diverse portfolio features a first-in-class oral FSH receptor agonist designed to optimize fertility outcomes, alongside a novel JNK inhibitor targeting the underlying mechanisms of endometriosis. Furthermore, the firm is pioneering early-stage AMH-targeting antibodies to provide greater control over ovarian folliculogenesis. By leveraging cutting-edge research, Celmatix is effectively redefining the standard of care for conditions such as Polycystic Ovary Syndrome (PCOS), positioning itself as a high-authority entity in the biotech landscape.
How much funding has Celmatix raised?
Celmatix has raised a total of $54.1M across 9 funding rounds:
Private Equity
$806K
Series A
$1.5M
Private Equity
$4M
Private Equity
$5.5M
Private Equity
$3.8M
Private Equity
$4.8M
Private Equity
$21M
Other Financing Round
$12.5M
Private Equity (2011): $806K, investors not publicly disclosed
Series A (2012): $1.5M supported by Topspin Partners
Private Equity (2013): $4M, investors not publicly disclosed
Private Equity (2014): $5.5M, investors not publicly disclosed
Private Equity (2015): $3.8M, investors not publicly disclosed
Private Equity (2016): $4.8M, investors not publicly disclosed
Private Equity (2016): $21M supported by Topspin Partners
Other Financing Round (2017): $12.5M featuring Topspin Partners
Key Investors in Celmatix
Topspin Partners
Topspin Consumer Partners is a private equity firm dedicated to growing branded consumer products and services companies. They partner with founder-owners and executive teams to facilitate company growth through strategic guidance, operational improvements, and capital access.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Celmatix?
With the recent infusion of capital, Celmatix is well-positioned to scale its R&D operations and advance its lead candidates through the regulatory pipeline. The strategic focus will likely remain on clinical validation and the commercialization of its therapeutic assets. As the company matures, it is expected to continue its pursuit of strategic partnerships and potential licensing agreements to maximize the reach of its innovative treatments. The ongoing commitment to female-centric drug discovery ensures that Celmatix remains a key innovator, poised to disrupt traditional fertility and reproductive health markets through scientific rigor and targeted therapeutic development.
See full Celmatix company page
